Bionime Corp (4737.TW) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · Taiwan · ISIN TW0004737002

Price
60.40 TWD
Market cap
4.67 bn TWD
P/E (2025)
–
P/S (2025)
2.54
Dividend yield
0.00 %
Net margin
-9.81 %
Return on equity (ROE)
-10.33 %
Return on assets (ROA)
-3.16 %

Bionime Corp financials

Fiscal year20242025
Revenue1.93 bn TWD1.84 bn TWD
Gross profit768.38 m TWD627.81 m TWD
Operating income-129.05 m TWD-197.36 m TWD
EBIT-123.52 m TWD-197.36 m TWD
Net income-127.22 m TWD-180.28 m TWD
Diluted EPS – continuing operations-1.90 TWD-2.65 TWD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Bionime Corp

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTEST brand; a continuous glucose monitoring system under the iFree CGM brand; and medical blood glucose management systems. It is also involved in the provision of biotechnology services; drug testing; examination of pharmaceutical products; and the sale of precision instruments. The company also provides wholesale medical devices, biotechnology services, pharmaceutical testing, and wholesale of precision instruments. Bionime Corporation was incorporated in 2003 and is based in Taichung, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.